210 related articles for article (PubMed ID: 14671195)
1. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.
Mauras N; Lima J; Patel D; Rini A; di Salle E; Kwok A; Lippe B
J Clin Endocrinol Metab; 2003 Dec; 88(12):5951-6. PubMed ID: 14671195
[TBL] [Abstract][Full Text] [Related]
2. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.
Valle M; Di Salle E; Jannuzzo MG; Poggesi I; Rocchetti M; Spinelli R; Verotta D
Br J Clin Pharmacol; 2005 Mar; 59(3):355-64. PubMed ID: 15752382
[TBL] [Abstract][Full Text] [Related]
3. Exemestane in advanced breast cancer.
Buzdar A
Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
[TBL] [Abstract][Full Text] [Related]
4. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
[TBL] [Abstract][Full Text] [Related]
5. [Phase I single-dose administration study of exemestane in postmenopausal women].
Miura S; Tominaga T; Koyama H; Nomura Y; Tsuboi M
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1179-87. PubMed ID: 12145999
[TBL] [Abstract][Full Text] [Related]
6. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Evans TR; Di Salle E; Ornati G; Lassus M; Benedetti MS; Pianezzola E; Coombes RC
Cancer Res; 1992 Nov; 52(21):5933-9. PubMed ID: 1394219
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Traina TA; Poggesi I; Robson M; Asnis A; Duncan BA; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler MN
Breast Cancer Res Treat; 2008 Sep; 111(2):377-88. PubMed ID: 17952589
[TBL] [Abstract][Full Text] [Related]
8. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor].
Tahara M; Nomura S; Hashimoto M
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):345-54. PubMed ID: 14501171
[TBL] [Abstract][Full Text] [Related]
10. The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors.
Bahrami N; Sauer T; Engebretsen S; Aljabri B; Bemanian V; Lindstrøm J; Lüders T; Kristensen V; Lorentzen A; Loeng M; Ødegård HP; Kvaløy JØ; Vestøl IB; Geisler SB; Gravdehaug B; Gundersen JM; Geisler J
Future Oncol; 2019 Nov; 15(32):3675-3682. PubMed ID: 31513453
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning PE
Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
[TBL] [Abstract][Full Text] [Related]
13. Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits.
Beltrame D; di Salle E; Giavini E; Gunnarsson K; Brughera M
Reprod Toxicol; 2001; 15(2):195-213. PubMed ID: 11297878
[TBL] [Abstract][Full Text] [Related]
14. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
15. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Bahrami N; Chang G; Kanaya N; Sauer T; Park D; Loeng M; Gravdehaug B; Chen S; Geisler J
J Steroid Biochem Mol Biol; 2020 Jun; 200():105641. PubMed ID: 32151708
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
Miller WR; Dixon JM
Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
[TBL] [Abstract][Full Text] [Related]
17. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and clinical experience with exemestane.
Lønning PE
Expert Opin Investig Drugs; 2000 Aug; 9(8):1897-905. PubMed ID: 11060785
[TBL] [Abstract][Full Text] [Related]
19. Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
Lombardi P
Biochim Biophys Acta; 2002 Jul; 1587(2-3):326-37. PubMed ID: 12084475
[TBL] [Abstract][Full Text] [Related]
20. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
